Compare Global X Copper Miners ETF (COPX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs ResMed Inc. — how do they compare? Global X Copper Miners ETF trades at $85.07 (market cap $7.10B), while ResMed Inc. trades at $228.3 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 4.5× Global X Copper Miners ETF's market cap, and ResMed Inc. pays a 1.16% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and ResMed Inc. for 51 Days on average.
| COPX | RMD | |
|---|---|---|
Market Cap | $7.10B | $31.89B |
Volume | 2,871,128 | 618,314 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $277.88 |
52-Week Low | $57.43 | $182.82 |
Typical Hold Time | 50 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX trades at $84.83, up 1.5% today, but technical indicators show a bearish trend with 17 sell signals versus 2 buy signals. The ETF faces resistance at $85 with support at $79. Recent news highlights copper's strategic importance for AI infrastructure and electrification, though analysts express caution about near-term global surplus projections despite strong copper price fundamentals.
The copper miner ETF offers exposure to the AI-driven copper demand story but faces headwinds from Federal Reserve policy uncertainty and potential global supply surpluses. While long-term electrification trends support the investment thesis, near-term volatility and miner underperformance relative to copper prices present both opportunity and risk for investors.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
